



## Upgrade your cell-free DNA experience

February 23, 2019

*Know more. Learn how we have improved our Innatal® Prenatal Screen.*

Progenity is dedicated to continuous product improvement. We have upgraded the Innatal Prenatal screen with the latest sequencing technology and improved chemistry.

In-depth verification and validation testing of the Innatal assay, using >1000 samples, was conducted as prescribed by multiple peer-reviewed guidelines.<sup>1,2,3</sup>

### What did we find?


#### The Innatal Prenatal Screen is:

**Precise** – Agreement of >99% for repeatability and reproducibility<sup>4</sup>

**Accurate** – High concordance with known clinical outcomes<sup>4</sup>

**Sensitive** – Proven to identify affected fetuses with >99% sensitivity<sup>4</sup>

**Specific** – Proven to rule-out unaffected fetuses with >99% specificity<sup>4</sup>



### Data Summary Sheet

A detailed summary of our verification and validation results.

[Download the data summary sheet](#) >



### **Have questions?**

Dive deeper on how this data uniquely impacts your practice by contacting us. We'll give you direct access to our lab team.

[Email us](#) >

### **References**

1. Jennings et al. Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med. 2009;133(5):743-55.
2. Lacbawan et al. Verification of performance specifications of a molecular test: cystic fibrosis carrier testing using the Luminex liquid bead array. Arch Pathol Lab Med. 2012;136(1):14-9.
3. Rehm et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013;15(9):733-47.
4. Progenity, Inc. Data on file.